amlexanox has been researched along with Obesity in 7 studies
amlexanox: SRA-A antagonist;structure given in first source
amlexanox : A pyridochromene-derived monocarboxylic acid having an amino substituent at the 2-position, an oxo substituent at the 5-position and an isopropyl substituent at the 7-position.
Obesity: A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).
| Excerpt | Relevance | Reference |
|---|---|---|
| "These effects were mediated by the breast cancer oncogene IKKε and its downstream target-the serine biosynthesis pathway as demonstrated by genetic or pharmacological tools." | 1.56 | Macrophages induce malignant traits in mammary epithelium via IKKε/TBK1 kinases and the serine biosynthesis pathway. ( Bentham, RB; Bianchi, K; Carter, E; Dalli, J; Godinho, SA; Grose, R; Hodivala-Dilke, K; Holdsworth, J; Ironside, A; Jones, L; Jones, W; Mataloni, I; Moreno Béjar, R; Szabadkai, G; Uhlik, L; Wilcz-Villega, E; Xu, R, 2020) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 6 (85.71) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Reilly, SM | 4 |
| Chiang, SH | 2 |
| Decker, SJ | 1 |
| Chang, L | 3 |
| Uhm, M | 2 |
| Larsen, MJ | 1 |
| Rubin, JR | 1 |
| Mowers, J | 2 |
| White, NM | 1 |
| Hochberg, I | 1 |
| Downes, M | 2 |
| Yu, RT | 1 |
| Liddle, C | 2 |
| Evans, RM | 2 |
| Oh, D | 1 |
| Li, P | 1 |
| Olefsky, JM | 1 |
| Saltiel, AR | 4 |
| Beyett, TS | 1 |
| Gan, X | 1 |
| Gomez, AV | 2 |
| Tesmer, JJG | 1 |
| Showalter, HD | 1 |
| Wilcz-Villega, E | 1 |
| Carter, E | 1 |
| Ironside, A | 1 |
| Xu, R | 1 |
| Mataloni, I | 1 |
| Holdsworth, J | 1 |
| Jones, W | 1 |
| Moreno Béjar, R | 1 |
| Uhlik, L | 1 |
| Bentham, RB | 1 |
| Godinho, SA | 1 |
| Dalli, J | 1 |
| Grose, R | 1 |
| Szabadkai, G | 1 |
| Jones, L | 1 |
| Hodivala-Dilke, K | 1 |
| Bianchi, K | 1 |
| Oral, EA | 1 |
| Meral, R | 1 |
| Butz, L | 1 |
| Ajluni, N | 1 |
| Chenevert, TL | 1 |
| Korytnaya, E | 1 |
| Neidert, AH | 1 |
| Hench, R | 1 |
| Rus, D | 1 |
| Horowitz, JF | 1 |
| Poirier, B | 1 |
| Zhao, P | 1 |
| Lehmann, K | 1 |
| Jain, M | 1 |
| Yu, R | 1 |
| Ahmadian, M | 1 |
| Cruz, VH | 1 |
| Arner, EN | 1 |
| Wynne, KW | 1 |
| Scherer, PE | 1 |
| Brekken, RA | 1 |
| Calay, ES | 1 |
| Hotamisligil, GS | 1 |
| Simon, J | 1 |
| Leto, D | 1 |
1 trial available for amlexanox and Obesity
| Article | Year |
|---|---|
Inhibition of IKKɛ and TBK1 Improves Glucose Control in a Subset of Patients with Type 2 Diabetes.
Topics: Aged; Aminopyridines; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Metaboli | 2017 |
6 other studies available for amlexanox and Obesity
| Article | Year |
|---|---|
An inhibitor of the protein kinases TBK1 and IKK-ɛ improves obesity-related metabolic dysfunctions in mice.
Topics: Aminopyridines; Animals; Anti-Allergic Agents; Anti-Obesity Agents; Cell Line; Diet, High-Fat; Energ | 2013 |
Design, synthesis, and biological activity of substituted 2-amino-5-oxo-5H-chromeno[2,3-b]pyridine-3-carboxylic acid derivatives as inhibitors of the inflammatory kinases TBK1 and IKKε for the treatment of obesity.
Topics: 3T3-L1 Cells; Amination; Animals; Anti-Obesity Agents; Chromans; Crystallography, X-Ray; Drug Design | 2018 |
Macrophages induce malignant traits in mammary epithelium via IKKε/TBK1 kinases and the serine biosynthesis pathway.
Topics: Aminopyridines; Animals; Breast Neoplasms; Culture Media, Conditioned; Epithelial Cells; Female; Hum | 2020 |
Loss of Tbk1 kinase activity protects mice from diet-induced metabolic dysfunction.
Topics: Aminopyridines; Animals; Body Weight; Diet, High-Fat; Disease Models, Animal; Fatty Liver; I-kappa B | 2018 |
Turning off the inflammatory, but not the metabolic, flames.
Topics: Aminopyridines; Animals; Anti-Obesity Agents; Energy Metabolism; I-kappa B Kinase; Insulin Resistanc | 2013 |
Inflammation produces catecholamine resistance in obesity via activation of PDE3B by the protein kinases IKKε and TBK1.
Topics: 3T3-L1 Cells; Adipocytes; Adipose Tissue, White; Adrenergic beta-3 Receptor Agonists; Aminopyridines | 2013 |